- Home
- ETNB vs EMBC Comparison
ETNB vs EMBC Comparison
Compare ETNB & EMBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ETNB
- EMBC
- Stock Information
- Founded
- ETNB 2018
- EMBC 1924
- Country
- ETNB United States
- EMBC United States
- Employees
- ETNB N/A
- EMBC N/A
- Industry
- ETNB Biotechnology: Pharmaceutical Preparations
- EMBC Medical/Dental Instruments
- Sector
- ETNB Health Care
- EMBC Health Care
- Exchange
- ETNB Nasdaq
- EMBC Nasdaq
- Market Cap
- ETNB 867.4M
- EMBC 753.0M
- IPO Year
- ETNB 2019
- EMBC N/A
- Fundamental
- Price
- ETNB $8.04
- EMBC $19.93
- Analyst Decision
- ETNB Buy
- EMBC Buy
- Analyst Count
- ETNB 7
- EMBC 2
- Target Price
- ETNB $30.33
- EMBC $19.00
- AVG Volume (30 Days)
- ETNB 800.5K
- EMBC 491.4K
- Earning Date
- ETNB 11-07-2024
- EMBC 02-07-2025
- Dividend Yield
- ETNB N/A
- EMBC 3.02%
- EPS Growth
- ETNB N/A
- EMBC 9.84
- EPS
- ETNB N/A
- EMBC 1.34
- Revenue
- ETNB N/A
- EMBC $1,123,100,000.00
- Revenue This Year
- ETNB N/A
- EMBC $1.77
- Revenue Next Year
- ETNB N/A
- EMBC $1.14
- P/E Ratio
- ETNB N/A
- EMBC $14.81
- Revenue Growth
- ETNB N/A
- EMBC 0.21
- 52 Week Low
- ETNB $7.00
- EMBC $9.93
- 52 Week High
- ETNB $16.63
- EMBC $21.48
- Technical
- Relative Strength Index (RSI)
- ETNB 44.02
- EMBC 60.29
- Support Level
- ETNB $7.44
- EMBC $19.16
- Resistance Level
- ETNB $8.09
- EMBC $20.22
- Average True Range (ATR)
- ETNB 0.44
- EMBC 0.91
- MACD
- ETNB -0.06
- EMBC -0.12
- Stochastic Oscillator
- ETNB 22.47
- EMBC 22.27
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).
About EMBC Embecta Corp.
Embecta Corp is a medical technology company. The company develops innovative technology, services, and solutions that help advance both clinical therapy for patients and clinical processes for healthcare providers. Its products include BD Pyxis, PureWick, Phasix among others.